Very rarely, patients who died with severe underlying disease and who had received multiple-dose fluconazole had post-mortem findings which included hepatic necrosis. These patients were receiving multiple concomitant medications, some known to be potentially hepatotoxic and/or had underlying diseases which could have caused the hepatic necrosis. Consequently, because a causal relationship with fluconazole cannot be excluded, in those patients in whom a significant rise of liver enzymes occurs, the risk-benefit ratio of continued fluconazole treatment should be assessed. In rare cases, as with other azoles, anaphylaxis has been reported.
Use in children:
Limited data are available on the use of fluconazole in children below 16 years; therefore, use at present is not recommended in these patients unless antifungal treatment is imperative and no suitable alternative agents exist. There are only limited data on the use of fluconazole in neonates, and its use in children below 1 year old is therefore not
Driving/Use of Machinery: Experience with fluconazole indicates that therapy is unlikely to impair a patient's ability to drive or use machinery.